

## Xcopri - (12.5, 25, 50, 100, 150 and 200 mg ; Tablet)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | Cenobamate   | <b>Innovator</b>            | SK Life             |
| <b>Dosage</b>                | 12.5, 25, 50, 100, 150 and 200 mg ; Tablet   | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5  | <b>Tentative Approvals</b>  | None                |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.